Evidence map›Paper›PMID 26446603›Full record

ArticleJournal of virology2016

Distinct Escape Pathway by Hepatitis C Virus Genotype 1a from a Dominant CD8+ T Cell Response by Selection of Altered Epitope Processing.

Andreas Walker, Kathrin Skibbe, Eike Steinmann, Stephanie Pfaender, Thomas Kuntzen, Dominik A Megger, Svenja Groten, Barbara Sitek, Georg M Lauer, Arthur Y Kim and 3 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Frontiers in microbiology · 2024
    Article
  2. Article
  3. Review
  4. Immune escape pathways from the HBV coreFrontiers in immunology · 2022
    Article
  5. Review
  6. Review
  7. Adaptive Immune Response against Hepatitis C Virus.International journal of molecular sciences · 2020
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Andreas WalkerInstitute for Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany.
Kathrin SkibbeInstitute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Eike SteinmannInstitute of Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hanover and the Helmholtz Centre for Infection Research, Hanover, Germany.
Stephanie PfaenderInstitute of Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hanover and the Helmholtz Centre for Infection Research, Hanover, Germany.
Thomas KuntzenRagon Institute of MGH, MIT, and Harvard, Charlestown, Massachusetts, USA.
Dominik A MeggerMedizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany.
Svenja GrotenInstitute of Virology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Barbara SitekMedizinisches Proteom-Center, Ruhr-Universität Bochum, Bochum, Germany.
Georg M LauerGastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Arthur Y KimDivision of Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Thomas PietschmannInstitute of Experimental Virology, Twincore Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hanover and the Helmholtz Centre for Infection Research, Hanover, Germany.
Todd M AllenRagon Institute of MGH, MIT, and Harvard, Charlestown, Massachusetts, USA.
Joerg TimmInstitute for Virology, Heinrich-Heine-University, University Hospital, Düsseldorf, Germany joerg.timm@med.uni-duesseldorf.de.
Helmholtz Centre for Infection Research · DEDüsseldorf University Hospital · DEHarvard University · USRagon Institute of MGH, MIT and Harvard · USRuhr University Bochum · DEUniversity of Duisburg-Essen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledAntiviral CD8(+) T cells are a key component of the adaptive immune response against HCV, but their impact on viral control is influenced by preexisting viral variants in important target epitopes and the development of viral escape mutations. Immunodominant epitopes highly conserved across genotypes therefore are attractive for T cell based prophylactic vaccines. Here, we characterized the CD8(+) T cell response against the highly conserved HLA-B*51-restricted epitope IPFYGKAI1373-1380 located in the helicase domain of NS3 in people who inject drugs (PWID) exposed predominantly to HCV genotypes 1a and 3a. Despite this epitope being conserved in both genotypes, the corresponding CD8(+) T cell response was detected only in PWID infected with genotype 3a and HCV-RNA negative PWID, but not in PWID infected with genotype 1a. In genotype 3a, the detection of strong CD8(+) T cell responses was associated with epitope variants in the autologous virus consistent with immune escape. Analysis of viral sequences from multiple cohorts confirmed HLA-B*51-associated escape mutations inside the epitope in genotype 3a, but not in genotype 1a. Here, a distinct substitution in the N-terminal flanking region located 5 residues upstream of the epitope (S1368P; P = 0.00002) was selected in HLA-B*51-positive individuals. Functional assays revealed that the S1368P substitution impaired recognition of target cells presenting the endogenously processed epitope. The results highlight that, despite an epitope being highly conserved between two genotypes, there are major differences in the selected viral escape pathways and the corresponding T cell responses. IMPORTANCE: HCV is able to evolutionary adapt to CD8(+) T cell immune pressure in multiple ways. Beyond selection of mutations inside targeted epitopes, this study demonstrates that HCV inhibits epitope processing by modification of the epitope flanking region under T cell immune pressure. Selection of a substitution five amino acids upstream of the epitope underlines that efficient antigen presentation strongly depends on its larger sequence context and that blocking of the multistep process of antigen processing by mutation is exploited also by HCV. The pathways to mutational escape of HCV are to some extent predictable but are distinct in different genotypes. Importantly, the selected escape pathway of HCV may have consequences for the destiny of antigen-specific CD8(+) T cells.

Indexed as

Immune EvasionMutationCD8-Positive T-LymphocytesCohort StudiesDEAD-box RNA HelicasesGenotypeHepacivirusHepatitis CHLA-B51 AntigenHumansImmunodominant EpitopesNucleoside-TriphosphataseSerine EndopeptidasesSubstance Abuse, IntravenousViral Nonstructural ProteinsViral ProteasesDEAD-box RNA HelicasesHLA-B51 AntigenImmunodominant EpitopesNS3 protein, hepatitis C virusNucleoside-TriphosphataseSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases

Identifiers

PMID26446603
PMCPMC4702586
OpenAlexW2273620166

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.